Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference

The new mini-textbook by Kamps & Hoffmann
PDF, 110 pages

  Malignant Melanoma

  Free Subscription


1 Arch Pathol Lab Med
1 Biochem Biophys Res Commun
1 Br J Cancer
1 Cancer Res
1 Clin Cancer Res
3 Cutis
1 J Am Acad Dermatol
1 J Clin Oncol
1 Melanoma Res
1 N Engl J Med
1 Nat Med
1 Oncogene
1 PLoS Comput Biol
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Arch Pathol Lab Med

  1. ELDER DE, Bastian BC, Cree IA, Massi D, et al
    The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway.
    Arch Pathol Lab Med. 2020 Feb 14. doi: 10.5858/arpa.2019-0561.
    PubMed     Text format     Abstract available

    Biochem Biophys Res Commun

  2. TANAKA Y, Takenouchi T, Tsukimoto M
    Mesencephalic astrocyte-derived neurotrophic factor is a novel radioresistance factor in mouse B16 melanoma.
    Biochem Biophys Res Commun. 2020 Feb 10. pii: S0006-291X(20)30252.
    PubMed     Text format     Abstract available

    Br J Cancer

  3. AYA-BONILLA CA, Morici M, Hong X, McEvoy AC, et al
    Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells.
    Br J Cancer. 2020 Feb 10. pii: 10.1038/s41416-020-0750.
    PubMed     Text format     Abstract available

    Cancer Res

  4. DANG N, Lin Y, Rutgeerts O, Sagaert X, et al
    Solid tumor-induced immune regulation alters the GvHD/GvT paradigm after allogenic bone marrow transplantation.
    Cancer Res. 2019 Apr 1. pii: 0008-5472.CAN-18-3143.
    PubMed     Text format     Abstract available

    Clin Cancer Res

  5. LI C, Guo W, Ma J, Yang Y, et al
    ATP-citrate lyase epigenetically potentiates oxidative phosphorylation to promote melanoma growth and adaptive resistance to MAPK inhibition.
    Clin Cancer Res. 2020 Feb 7. pii: 1078-0432.CCR-19-1359.
    PubMed     Text format     Abstract available


  6. HEMPERLY S, Ermolovich T, Lountzis NI, Sheikh HA, et al
    Darkening and eruptive nevi during treatment with erlotinib.
    Cutis. 2019;104:E19-E21.
    PubMed     Text format    

  7. TAN A, Stein JA
    Dermoscopic patterns of acral melanocytic lesions in skin of color.
    Cutis. 2019;103:274-276.
    PubMed     Text format     Abstract available

  8. SRIVASTAVA R, Wassef C, Rao BK
    The Dayanara effect: increasing skin cancer awareness in the Hispanic community.
    Cutis. 2019;103:257-258.
    PubMed     Text format    

    J Am Acad Dermatol

  9. LEE MH, Kim YJ, Yun KA, Won CH, et al
    Prognostic Significance of CD200 Protein Expression and its Correlation with COX-2 in Cutaneous Melanoma.
    J Am Acad Dermatol. 2020 Feb 7. pii: S0190-9622(20)30210.
    PubMed     Text format    

    J Clin Oncol

  10. BETOF WARNER A, Palmer JS, Shoushtari AN, Goldman DA, et al
    Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.
    J Clin Oncol. 2020 Feb 13:JCO1901464. doi: 10.1200/JCO.19.01464.
    PubMed     Text format     Abstract available

    Melanoma Res

  11. HUYNH S, Lheure C, Franck N, Goldman-Levy G, et al
    Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study.
    Melanoma Res. 2019 Oct 25. pii: 00008390-900000000-99122.
    PubMed     Text format     Abstract available

    N Engl J Med

  12. APOSTOLOVA P, Unger S, von Bubnoff D, Meiss F, et al
    Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy.
    N Engl J Med. 2020;382:294-296.
    PubMed     Text format    

    Nat Med

  13. FAIRFAX BP, Taylor CA, Watson RA, Nassiri I, et al
    Peripheral CD8(+) T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.
    Nat Med. 2020;26:193-199.
    PubMed     Text format     Abstract available


  14. XU Z, Li L, Qian Y, Song Y, et al
    Upregulation of IL-6 in CUL4B-deficient myeloid-derived suppressive cells increases the aggressiveness of cancer cells.
    Oncogene. 2019;38:5860-5872.
    PubMed     Text format     Abstract available

    PLoS Comput Biol

  15. CASSIDY T, Craig M
    Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization.
    PLoS Comput Biol. 2019;15:e1007495.
    PubMed     Text format     Abstract available

    PLoS One

  16. RABIN-COURT A, Rodrigues MR, Zhang XM, Perry RJ, et al
    Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidation.
    PLoS One. 2019;14:e0218126.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.